ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)

Rhea-AI Summary

ChromaDex (NASDAQ: CDXC) is enhancing awareness of its research at key conferences, including ASN Nutrition 2022, ISSN, and FASEB’s NAD+ Metabolism and Signaling Conference. The company’s CERP™ program has over 250 material transfer agreements with 235 scientists across 182 institutions. During ASN, presentations will cover topics like NAD+ impact on immune function and cognition. ChromaDex’s involvement aims to highlight the importance of nicotinamide riboside, a precursor to NAD+, for healthy aging and athletic performance.

As a pioneer of nicotinamide adenine dinucleotide (NAD⁺) and healthy aging research, ChromaDex aims to raise awareness amongst industry leaders

LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CERP™) investigators, will be presenting at several key scientific conferences including the American Society for Nutrition’s (ASN) Nutrition 2022, the International Society of Sports Nutrition (ISSN) annual meeting, and Federation of American Societies for Experimental Biology (FASEB), The NAD⁺ Metabolism and Signaling Conference. CERP™ is a pioneering program in nicotinamide adenine dinucleotide (NAD⁺) research and healthy aging and most recently celebrated over 250 material transfer agreements with over 235 independent scientists, doctors, and investigators across 182 institutions and 33 countries. Many of the agreements were developed to study Niagen®, ChromaDex’s proprietary nicotinamide riboside (NR) ingredient, an efficient precursor for the essential cellular coenzyme, NAD⁺. ChromaDex aims to raise awareness of this research at ASN, ISSN and FASEB.

Below is an overview of how ChromaDex will be participating in each event.

American Society for Nutrition, Nutrition 2022, June 14-16, 2022 (Virtual):

ChromaDex and co-sponsor Balchem are sponsoring the Satellite Program, Exploring the Role of Selected Vitamins and Essential Nutrients in Cognition: Impact of Supplementation on Neurodegeneration, which takes place today on June 15 from 12:00-1:30pm EDT. The discussion will feature two CERP™ investigators, Dr. Charalampos Tzoulis (Clinical Neurologist and Professor of Neurology & Neurogenetics, Haukeland University Hospital, University of Bergen, Norway), and Dr. Vilhelm Bohr (Retired Laboratory Chief, Laboratory of Molecular Gerontology, National Institutes on Aging, National Institutes of Health in Baltimore, Maryland) alongside Dr. Jim Ray (Executive Director Neuroscience, The Neurodegeneration Consortium, MD Anderson Cancer Center in Houston, Texas).

In addition, three ChromaDex employees will be presenting at the conference: Rebecca Idoine, CERP™ Specialist at ChromaDex, will present in the session Impact of Boosting NAD⁺ on Immune Function: Results from Nicotinamide Riboside Preclinical Studies (Oral Talk); Jun Kwon, a CERP™ Scientist at ChromaDex, will speak at The Clinical Effects of Nicotinamide Riboside on Inflammatory Parameters (Poster); and Dr. Yasmeen Nkrumah-Elie, Global Director of External Research for ChromaDex, will speak at Nicotinamide Riboside Supports Brain Health: Assessing the Evidence.

International Society of Sports Nutrition (ISSN), June 16 – 18, 2022, (Fort Lauderdale Beach, Florida):

ChromaDex’s Mona Rosene, MS, RD and Global Director of Scientific Affairs, will be presenting on NAD⁺, Muscle, and Athletic Performance: Current Research and Future Needs. Her presentation will provide an overview of clinical research and future research needs to better understand the role of NAD⁺ and NAD⁺ precursors in muscle and exercise performance.

Federation of American Societies for Experimental Biology: The NAD⁺ Metabolism and Signaling Conference, June 26 – 30, 2022 (Steamboat Springs, Colorado):

ChromaDex will engage with scientists from multiple disciplines to share the latest findings in NAD⁺ metabolism and signaling related to human health, disease, and medicine. ChromaDex has two abstract submissions accepted, one of which Dr. Yasmeen Nkrumah-Elie, Global Director of External Research for ChromaDex, will be presenting as a short talk titled, “Effect of nicotinamide riboside supplementation on cognition and related outcomes in a group of healthy older adults.” Her talk will be held during Session 9: NAD⁺ Metabolism and Interventions in Aging and Disease, on Thursday, June 30, along with Dr. Charles Brenner, ChromaDex’s Chief Scientific Advisor on the Scientific Advisory Board, who will be discussing nicotinamide riboside in physiology and therapeutics.

The second abstract, authored by Yusrah Istiaq, Scientific Affairs Manager at ChromaDex, will be presented as a poster by Aron Erickson, Vice President of Research and Development at ChromaDex, titled, “Mean Baseline NAD⁺ In Human Biofluids and Tissues: An Evaluation of the Clinical Evidence.”

Lastly, ChromaDex is sponsoring a social hour event on Tuesday, June 28, between 4:00-6:00pm MT, where attendees will enjoy appetizers and a short presentation from Dr. Nkrumah-Elie.

For additional information on ChromaDex, visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD⁺), levels of which decline with age. ChromaDex is the innovator behind NAD⁺ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD⁺ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to increasing awareness of the Company’s research. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005196/en/

ChromaDex Media Contact:

Kendall Knysch, Director of Media Relations

310-388-6706 ext. 689

kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:

Brianna Gerber, Vice President of Finance and Investor Relations

949-419-0288 ext. 127

briannag@chromadex.com

Source: ChromaDex Corporation

FAQ

What is ChromaDex's role in scientific conferences in 2022?

ChromaDex is presenting research at ASN Nutrition 2022, ISSN annual meeting, and FASEB's NAD+ Metabolism and Signaling Conference to raise awareness about NAD+ and its health benefits.

What is the CERP program mentioned in ChromaDex's press release?

The CERP program is ChromaDex's initiative for research on nicotinamide adenine dinucleotide (NAD+) involving over 250 material transfer agreements with 235 scientists.

What topics will be covered by ChromaDex at ASN Nutrition 2022?

ChromaDex will discuss NAD+ effects on immune function, cognition, and the benefits of nicotinamide riboside at the ASN Nutrition 2022 conference.

When is the FASEB NAD+ Metabolism and Signaling Conference?

The FASEB NAD+ Metabolism and Signaling Conference will take place from June 26 to June 30, 2022, in Steamboat Springs, Colorado.

What is nicotinamide riboside and its relevance to ChromaDex?

Nicotinamide riboside is a precursor to NAD+ and is crucial for healthy aging; it is ChromaDex's flagship ingredient, commercialized as Niagen®.